1-12 of 12
Yohann Loriot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu, Tibor Csöszi, Yohann Loriot, Alejo Rodriguez-Vida, Lajos Géczi, Susanna Y. Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Seyda Gunduz, Ronac Mamtani, Evan Y. Yu, Alvaro Montesa Pino, Urbano Anido, Mehmet A.N. Sendur, Gwenaelle Gravis, János Révész, Vladimir Kostorov, Olivier Huillard, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Jared Lunceford, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Nobuaki Matsubara
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5353–5364.
https://doi.org/10.1158/1078-0432.CCR-23-3518
Published: 02 December 2024
View articletitled, Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Open the PDF for Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4943–4956.
https://doi.org/10.1158/1078-0432.CCR-24-1834
Published: 01 November 2024
View articletitled, Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies
Open the PDF for Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies in another window
Includes: Supplementary data
Journal Articles

Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer

Yohann Loriot, Arjun V. Balar, Daniel P. Petrylak, Arash R. Kalebasty, Petros Grivas, Aude Fléchon, Rohit K. Jain, Umang Swami, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, Mitch Sierecki, Marianna Zavodovskaya, Emon Elboudwarej, Lauri Diehl, Juliane M. Jürgensmeier, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3179–3188.
https://doi.org/10.1158/1078-0432.CCR-23-3924
Published: 01 August 2024
View articletitled, Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Open the PDF for Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

Naoual Menssouri, Loïc Poiraudeau, Carole Helissey, Ludovic Bigot, Jonathan Sabio, Tony Ibrahim, Cédric Pobel, Claudio Nicotra, Maud Ngo-Camus, Ludovic Lacroix, Etienne Rouleau, Lambros Tselikas, Anne Chauchereau, Félix Blanc-Durand, Alice Bernard-Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Emeline Colomba, Alina Fuerea, Laurence Albiges, Pernelle Lavaud, Paul van de Wiel, Eveline den Biezen, Yvonne Wesseling-Rozendaal, Santiago Ponce, Stefan Michiels, Christophe Massard, Daniel Gautheret, Fabrice Barlesi, Fabrice André, Benjamin Besse, Jean-Yves Scoazec, Luc Friboulet, Karim Fizazi, Yohann Loriot
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4504–4517.
https://doi.org/10.1158/1078-0432.CCR-22-3736
Published: 01 November 2023
View articletitled, Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Open the PDF for Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, III, Sanjeev Mariathasan, Carol O'Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3360–3369.
https://doi.org/10.1158/1078-0432.CCR-20-1981
Published: 15 June 2021
View articletitled, Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Open the PDF for Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Aït Oukhatar, Natalie Hoog-Labouret, Frank de Kievit, Karen Howarth, Clive Morris, Emma Green, Luc Friboulet, Sylvie Chabaud, Jean-François Guichou, Maurice Perol, Benjamin Besse, Jean-Yves Blay, Pierre Saintigny, David Planchard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6242–6253.
https://doi.org/10.1158/1078-0432.CCR-20-1037
Published: 01 December 2020
View articletitled, Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer
Open the PDF for Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy

Daniel Petrylak, Jonathan Rosenberg, Ignacio Duran, Yohann Loriot, Guru Sonpavde, Chunzhang Wu, Elaina Gartner, Amal Melhem- Bertrandt, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): B26.
https://doi.org/10.1158/1557-3265.BLADDER19-B26
Published: 03 August 2020
View articletitled, Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy
Journal Articles

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 764–774.
https://doi.org/10.1158/1078-0432.CCR-19-2035
Published: 14 February 2020
View articletitled, Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Open the PDF for Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer

Marine F. Garrido, Nicolas J.-P. Martin, Matthieu Bertrand, Catherine Gaudin, Frédéric Commo, Nassif El Kalaany, Nader Al Nakouzi, Ladan Fazli, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Daniel Compagno, Martin Gleave, Yohann Loriot, Laurent Désaubry, Stéphan Vagner, Karim Fizazi, Anne Chauchereau
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 710–723.
https://doi.org/10.1158/1078-0432.CCR-18-0704
Published: 15 January 2019
View articletitled, Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Open the PDF for Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon, Jean-Yves Scoazec, Fabrice André, Jean-Charles Soria, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 5983–5991.
https://doi.org/10.1158/1078-0432.CCR-16-0917
Published: 15 December 2016
View articletitled, Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Open the PDF for Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

Yoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi, Fan Zhang, Alexander W. Wyatt, Nader Al Nakouzi, Fan Mo, Tianyuan Zhou, Youngsoo Kim, Brett P. Monia, A. Robert MacLeod, Ladan Fazli, Yuzhuo Wang, Colin C. Collins, Amina Zoubeidi, Martin Gleave
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1675–1687.
https://doi.org/10.1158/1078-0432.CCR-14-1108
Published: 31 March 2015
View articletitled, Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Open the PDF for Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth in another window
Includes: Supplementary data
Journal Articles

Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells

Francoise Farace, Melissa Taylor, Jochen Rössler, Yohann Loriot, Benjamin Besse
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6740.
https://doi.org/10.1158/1078-0432.CCR-09-1372
Published: 02 November 2009
View articletitled, Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells
Open the PDF for Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells in another window